PepGen Inc

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Urged To Join The Schall Law Firm In A Securities Fraud Investigation Into PepGen Inc

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D o.

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Invited To Lead The Schall Law Firm In The Securities Fraud Investigation Into PepGen Inc

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Encouraged To Lead The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Invited To Spearhead The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Invited To Join In The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Encouraged To Participate In The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG.

PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Invited To Join The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Welcome To Participate In The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors May Join The Schall Law Firm's Securities Fraud Investigation Into PepGen Inc

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.

PepGen Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - PEPG

NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.

PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Can Participate In The PepGen Inc Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.

ATTENTION PEPG SHAREHOLDERS: Investors Who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

PEPG Investors Eligible To Participate In The PepGen Inc Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.

Lost Money on PepGen Inc. (PEPG)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2024. “Our July readout of the CONNECT1 5 mg/kg clinical data in Duchenne muscular dystrophy (DMD) was the culmination of years of dedicated effort from our.

PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.

Levi & Korsinsky Reminds Shareholders of an Investigation into PepGen Inc. (PEPG) Regarding Potential Securities Fraud Allegations

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

PEPG Investors Can Participate In The PepGen Inc Securities Fraud Investigation With The Schall Law Firm

Levi & Korsinsky Reminds PepGen Investors of the Ongoing Investigation into Potential Violations of Securities Laws – PEPG

Investors who lost money on PepGen Inc. should contact Levi & Korsinsky about an ongoing investigation - PEPG

Levi & Korsinsky Announces an Investigation on Behalf of PepGen Inc. (PEPG) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen") (NASDAQ:PEPG) concerning possible violations of federal securities laws. On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51.

PEPG STOCK ALERT: Levi & Korsinsky Notifies PepGen Inc. Investors of an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for PepGen Inc Stock (PEPG)